business
Ultragenyx Wins FDA Approval For FAYUVI In Pediatric MPS IIIA
Ultragenyx Pharmaceutical Inc. (RARE) announced that the U.S. Food and Drug Administration (FDA) granted standard full approval of FAYUVI, also known as UX111, for treating pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
US stocks: S&P 500 ends nearly flat as US-Iran talks help stocks pare losses
economictimes.indiatimes.com
McDonald’s offers US$8.5 billion to help owners with overhaul
financialpost.com
Carney tells NYT he looked at ‘extreme tail risk’ of U.S. invasion
financialpost.com
Former VC Partner Hsin-Ju Chuang Dies at 37: What We Know So far
Cryptonews
Form 8.5 (EPT/RI)-Pollen Street Group Limited
Globenewswire_fr